BEIJING, April 29, 2026 /PRNewswire/ -- Concord Medical Services Holdings Limited (&#34;Concord Medical&#34; or the &#34;Company&#34;) (NYSE:CCM), a healthcare provider specialized in cancer treatment, research,

<p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">BEIJING</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">April 29, 2026</span> /PRNewswire/ -- Concord Medical Services Holdings Limited (&#34;Concord Medical&#34; or the &#34;Company&#34;) (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/CCM">CCM</a>), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 (the &#34;Annual Report&#34;) with the U.S. Securities and Exchange Commission (&#34;SEC&#34;). An electronic copy of the Annual Report can be accessed on Concord Medical&#39;s investor relations website at <i xmlns="http://www.w3.org/1999/xhtml"><a xmlns="http://www.w3.org/1999/xhtml" href="http://ir.ccm.cn/" target="_blank" rel="nofollow">http://ir.ccm.cn</a></i> and on the SEC&#39;s website at <a xmlns="http://www.w3.org/1999/xhtml" href="http://www.sec.gov/" target="_blank" rel="nofollow"><i xmlns="http://www.w3.org/1999/xhtml">www.sec.gov</i></a>. Shareholders may receive a hard copy of the Annual Report free of charge upon request. Requests should be submitted to <i xmlns="http://www.w3.org/1999/xhtml"><a xmlns="http://www.w3.org/1999/xhtml" href="http://ir.ccm.cn/" target="_blank" rel="nofollow">http://ir.ccm.cn</a></i>. </p>
<p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">About Concord Medical</b></p><p xmlns="http://www.w3.org/1999/xhtml">Concord Medical Services Holdings Limited is a healthcare provider featuring a full cycle of premium oncology services including cancer diagnosis, treatment, education and prevention. The Company focuses on providing multidisciplinary cancer care in all aspects of oncology healthcare services in its cancer hospitals and equipping them with technologically advanced equipment such as the state-of-the-art proton therapy system. The Company is striving to improve the quality and accessibility of cancer care through its network of self-owned cancer hospitals and clinics as well as partnered hospitals across China. For more information, please see <a xmlns="http://www.w3.org/1999/xhtml" href="http://ir.ccm.cn/" target="_blank" rel="nofollow">http://ir.ccm.cn</a>. </p>



<p xmlns="http://www.w3.org/1999/xhtml" id="PURL"><img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=CN46616&amp;sd=2026-04-29"></img> View original content:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/concord-medical-files-annual-report-on-form-20-f-for-the-fiscal-year-2025-302757128.html" target="_blank">https://www.prnewswire.com/news-releases/concord-medical-files-annual-report-on-form-20-f-for-the-fiscal-year-2025-302757128.html</a></p><p xmlns="http://www.w3.org/1999/xhtml">SOURCE Concord Medical Services Holdings Limited</p>

Concord Medical Files Annual Report on Form 20-F for the Fiscal Year 2025

Concord Medical Files 2025 Annual Report with SEC

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>BEIJING, April 29, 2026 /PRNewswire/ -- Concord Medical Services Holdings Limited (&amp;#34;Concord Medical&amp;#34; or the &amp;#34;Company&amp;#34;) (NYSE:CCM), a healthcare provider specialized in cancer treatment, research,</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Concord Medical Services recently filed its annual report for 2025 with the SEC, underscoring its ongoing commitment to transparency and growth in oncology care. This filing can enhance investor confidence and potentially affect stock performance as stakeholders assess the company&#039;s operational and financial health.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Concord Medical filed its 2025 annual report with the SEC.</li><li>The report is accessible on the company&#039;s and SEC&#039;s website.</li><li>Concord Medical focuses on oncology services in China.</li><li>The company aims to improve cancer care quality and accessibility.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Concord Medical Services Holdings Limited (CCM)</strong>: Focuses on premium oncology services in China.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This news falls under &#039;Corporate Developments&#039; as it relates to compliance and financial reporting, which is crucial for assessing investment viability in the healthcare sector.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>CCM&#039;s annual report may highlight improved financial performance.</li><li>Shares could rise if investors perceive strong market positioning in oncology.</li><li>Transparency and timely regulatory filing could attract institutional interest.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Annual report filed on April 29, 2026.</li><li>Covers the fiscal year ended December 31, 2025.</li><li>Concord Medical specializes in cancer diagnosis, treatment, and education.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>CCM presents a buying opportunity as its transparency may bolster investor confidence.</p>
  </section>
</section>


<p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">BEIJING</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">April 29, 2026</span> /PRNewswire/ -- Concord Medical Services Holdings Limited (&#34;Concord Medical&#34; or the &#34;Company&#34;) (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/CCM">CCM</a>), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 (the &#34;Annual Report&#34;) with the U.S. Securities and Exchange Commission (&#34;SEC&#34;). An electronic copy of the Annual Report can be accessed on Concord Medical&#39;s investor relations website at <i xmlns="http://www.w3.org/1999/xhtml"><a xmlns="http://www.w3.org/1999/xhtml" href="http://ir.ccm.cn/" target="_blank" rel="nofollow">http://ir.ccm.cn</a></i> and on the SEC&#39;s website at <a xmlns="http://www.w3.org/1999/xhtml" href="http://www.sec.gov/" target="_blank" rel="nofollow"><i xmlns="http://www.w3.org/1999/xhtml">www.sec.gov</i></a>. Shareholders may receive a hard copy of the Annual Report free of charge upon request. Requests should be submitted to <i xmlns="http://www.w3.org/1999/xhtml"><a xmlns="http://www.w3.org/1999/xhtml" href="http://ir.ccm.cn/" target="_blank" rel="nofollow">http://ir.ccm.cn</a></i>. </p>
<p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">About Concord Medical</b></p><p xmlns="http://www.w3.org/1999/xhtml">Concord Medical Services Holdings Limited is a healthcare provider featuring a full cycle of premium oncology services including cancer diagnosis, treatment, education and prevention. The Company focuses on providing multidisciplinary cancer care in all aspects of oncology healthcare services in its cancer hospitals and equipping them with technologically advanced equipment such as the state-of-the-art proton therapy system. The Company is striving to improve the quality and accessibility of cancer care through its network of self-owned cancer hospitals and clinics as well as partnered hospitals across China. For more information, please see <a xmlns="http://www.w3.org/1999/xhtml" href="http://ir.ccm.cn/" target="_blank" rel="nofollow">http://ir.ccm.cn</a>. </p>



<p xmlns="http://www.w3.org/1999/xhtml" id="PURL"><img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=CN46616&amp;sd=2026-04-29"></img> View original content:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/concord-medical-files-annual-report-on-form-20-f-for-the-fiscal-year-2025-302757128.html" target="_blank">https://www.prnewswire.com/news-releases/concord-medical-files-annual-report-on-form-20-f-for-the-fiscal-year-2025-302757128.html</a></p><p xmlns="http://www.w3.org/1999/xhtml">SOURCE Concord Medical Services Holdings Limited</p>

Concord Medical Services recently filed its annual report for 2025 with the SEC, underscoring its ongoing commitment to transparency and growth in oncology care. This filing can enhance investor confidence and potentially affect stock performance as stakeholders assess the company's operational and financial health.

Concord Medical Files Annual Report on Form 20-F for the Fiscal Year 2025

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News